Exchange: NASDAQ·Updated 04:28 PM EST

WVE News

News
all
press releases
WAVE Life Sciences Ltd. (NASDAQ:WVE) Stock Has Average Price Target of $20.44 According to Brokerages
WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) has received an average recommendation of "Moderate Buy" from the twenty research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recom...
MarketBeat
WAVE Life Sciences Ltd. (NASDAQ:WVE) Stock Has Average Price Target of $20.44 According to Brokerages
WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) has received an average recommendation of "Moderate Buy" from the twenty research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recom...
MarketBeat
More News
Wave Life Sciences (WVE) delivered earnings and revenue surprises of +11.77% and +342.29%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
Zacks
Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.read more...
Benzinga
(RTTNews) - On Tuesday, Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company based in RNA medicines, announced the appointment of Monika Vnuk as the Chief Business Officer, and will join Waves executive team and lead business development, corporate development, a...
Nasdaq News: Markets
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -9.68% and -73.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Wave Life Sciences (WVE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.
Zacks

Advertisement|Remove ads.